Stock Traders Buy High Volume of Oncology Institute Call Options (NASDAQ:STLN)

Oncology Institute, Inc. (NASDAQ:STLN) was the target of unusually large options trading on Tuesday. Stock traders acquired 10,914 call options on the stock. This is an increase of 365% compared to the typical volume of 2,346 call options.

Analyst Upgrades and Downgrades

Several analysts have issued reports on STLN shares. Needham & Company LLC boosted their price objective on Oncology Institute from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. BTIG Research raised their target price on shares of Oncology Institute from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday. B. Riley Financial reissued a “buy” rating and issued a $10.00 target price (down from $11.00) on shares of Oncology Institute in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Tuesday, November 3rd. Finally, Lake Street Capital reduced their price target on shares of Oncology Institute from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.25.

Oncology Institute Stock Up 6.4%

Shares of STLN stock traded up $0.26 on Tuesday, reaching $4.25. 4,032,692 shares of the company’s stock traded hands, compared to its average volume of 1,883,973. Oncology Institute has a 12-month low of $2.32 and a 12-month high of $7.13. The company has a market capitalization of $420.56 million, a P/E ratio of -14.69 and a beta of 0.44. The company has a 50 day moving average of $6.39.

Oncology Institute (NASDAQ:STLN) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $169.77 million during the quarter. On average, equities research analysts expect that Oncology Institute will post -0.21 EPS for the current year.

Insider Buying and Selling at Oncology Institute

In related news, major shareholder Jorey Chernett bought 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the acquisition, the insider directly owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. The trade was a 0.11% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Brad Hively sold 298,853 shares of Oncology Institute stock in a transaction on Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the transaction, the director owned 411,976 shares in the company, valued at $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in Oncology Institute in the 2nd quarter worth $41,000. AMG National Trust Bank bought a new stake in shares of Oncology Institute in the 2nd quarter valued at approximately $54,000. Engineers Gate Manager LP bought a new stake in shares of Oncology Institute in the 2nd quarter valued at approximately $67,000. Fermata Advisors LLC acquired a new position in shares of Oncology Institute in the 2nd quarter worth approximately $70,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Oncology Institute in the 2nd quarter worth approximately $102,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals. The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.